NIJMEGEN, the Netherlands – 14 September 2022: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, today announces that Prof. Dr. Jan Smeitink, Chief Executive Officer at Khondrion, will participate in the mitoNice international congress taking place in Nice, France, from tomorrow until Saturday 17 September.
Hosted by the French patient association, AFM-Téléthon, mitoNice is an international forum dedicated to mitochondrial medicine, bringing together more than 200 experts in the field who will share the latest research and progress in the development of innovative therapies to treat mitochondrial diseases.
Dr. Smeitink will join the plenary session, “New treatments for mitochondrial diseases: update on recent and current clinical trials”, on Saturday 17 September from 08:30 to 10:00am (CEST). His presentation, “Sonlicromanol in primary mitochondrial disease MELAS spectrum disorders”, will provide a development overview on sonlicromanol, Khondrion’s lead clinical asset.
Sonlicromanol is being developed to treat a range of mitochondrial diseases in children and adults. A first-in-class, oral small molecule, it targets key underlying mechanisms of mitochondrial disease based on its unique triple mode of action: redox modulation to help restore the cell’s metabolism, radical trapping preventing ferroptotic cell death, and mPGES-1 inhibition resulting in anti-inflammatory effects. Headline results from the Company’s Phase IIb programme, in adult patients with MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders, are expected later this year.
Prof. Dr. Jan Smeitink, Chief Executive Officer of Khondrion, commented: “This conference brings together physicians, researchers and patients from around the world and provides us with an important opportunity to discuss the latest research in mitochondrial disease and the current understanding around potential pathways towards diagnosis and treatment. This international exchange and collaboration between physicians, the scientific community and patients is key to developing the much-needed new treatment approaches to tackle these severe and debilitating diseases.”
For more information on, or to register for mitoNice, visit www.mitonice.org
